Human Apolipoprotein M ELISA , APOM
- Known as:
- Human Apolipoprotein M Enzyme-linked immunosorbent assay test , APOM
- Catalog number:
- E01A0522
- Product Quantity:
- 96 Tests/kit
- Category:
- -
- Supplier:
- BGene
- Gene target:
- Human Apolipoprotein ELISA APOM
Related genes to: Human Apolipoprotein M ELISA , APOM
- Gene:
- APOM NIH gene
- Name:
- apolipoprotein M
- Previous symbol:
- -
- Synonyms:
- ApoM, G3a, NG20
- Chromosome:
- 6p21.33
- Locus Type:
- gene with protein product
- Date approved:
- 2002-08-02
- Date modifiied:
- 2016-10-05
Related products to: Human Apolipoprotein M ELISA , APOM
Related articles to: Human Apolipoprotein M ELISA , APOM
- - Source: PubMed
Publication date: 2026/07/04
Heydari DanielDownie Mallory L - Developing proton exchange membranes (PEMs) that integrate high conductivity, selectivity, and processability is highly challenging. Although polyoxometalates (POMs) are promising proton conductors, their practical application is hindered by poor processability, susceptibility to leaching, and difficulty in forming continuous proton conduction pathways within polymers. Herein, a new photocurable polyoxometalate (POM)-organic membrane (PAPOM-AMPS) is synthesized via ultrafast UV-initiated copolymerization of an acrylamide-functionalized arsenomolybdate cluster (APOM), 2-acrylamido-2-methylpropanesulfonic acid (AMPS), and acrylic acid (AA). This molecular-level design ingeniously constructs hierarchical proton transport channels: the covalently immobilized APOM clusters serve as long-range highways, while sulfonic (-SOH) and carboxylic (-COOH) acid groups synergize with water molecules to facilitate efficient proton dissociation and dynamic short-range hopping. The membrane exhibits an exceptional proton conductivity of 0.417 S·cm at 80°C and 100% RH, surpassing Nafion 117. With confined ionic domains (∼2.27 nm), it achieves ultrahigh proton/vanadium selectivity (18.1 × 10 S·min·cm), 4.6 times that of Nafion 117. When configured into a sandwich-structured membrane for vanadium flow batteries (VFBs), it delivers outstanding performance, including 98.2% coulombic efficiency, 86.7% energy efficiency, and exceptional cycling stability (0.12% capacity decay per cycle at 120 mA·cm). This work provides a groundbreaking strategy for next-generation high-performance proton-conductive membranes. - Source: PubMed
Publication date: 2026/07/03
Mu XinYu FeiyangLiu TianwangQiu TianyuLi TianluSun ZhenLang ZhonglingLi YangguangWang YonghuiTan Huaqiao - Alcohol use disorder (AUD) is linked to cognitive deficits that can persist even after prolonged abstinence. Research highlighted associations between plasma apolipoproteins and cognition in AUD. This study examines the longitudinal evolution of plasma apolipoproteins and inflammation in AUD patients during early and prolonged abstinence and their association with cognitive recovery. Thirty-three AUD patients from an outpatient hospital alcoholism programme were evaluated at baseline (t = 0), 6 months (t = 1) and 12 months (t = 2), along with 34 healthy controls. Cognitive performance was assessed using the TEDCA test, which measures general cognitive function (GCF). Biological assessments included plasma pro-inflammatory biomarkers (LPS and LBP) and several apolipoproteins (APOAI, APOAII, APOB, APOCII, APOE, APOJ and APOM). AUD patients showed elevated plasma LPS, APOAI, APOE, APOJ and downregulated APOM, which all normalized at t = 1, whereas cognitive improvement was significant at t = 2 compared to controls. Mixed-effects models including all covariates and within-between person decomposition, followed by correlation matrix and reduced mixed models sensitivity analysis support robust associations between better GCF and (1) the duration of abstinence and (2) within-person reductions in LPS, although apolipoprotein changes should be considered exploratory at this level. Prolonged abstinence in AUD patients normalizes plasma peripheral inflammation and apolipoprotein levels and improves cognition. Although APOAI and APOM showed opposite trajectories, as opposite biomarkers in AUD diagnosis reported previously, only the duration of abstinence and normalization of within-person blood LPS levels over time emerged as predictors of cognitive recovery. - Source: PubMed
Escudero BertaOlmos RicardoArias FranciscoOrio Laura - To understand the mechanisms underlying the remarkable resistance of Göttingen minipigs to metabolic dysfunction-associated steatotic liver disease (MASLD), a multi-level transcriptomic analysis comparing their liver with those of humans, mice, and MASLD susceptible pig breeds was performed. This analysis revealed 692 genes uniquely differentially expressed in livers of Göttingen minipigs, linked to multiple metabolic and signaling pathways (e.g., AMPK signaling). Among these, 11 transcription factors, 3 hepatokines (DPP4, ITIH1, and ITIH3), and 6 additional secreted proteins (including PCSK9 and APOM) exhibited particularly strong differential expression and emerged as candidate mediators of MASLD resistance. This finding was further supported by weighted gene co-expression network analysis, which identified a core regulatory network driven by the transcription factors HMBOX1 and PATZ1, presumably regulating 41% of its differentially expressed genes. Collectively, these results suggest that a distinct transcriptional program involving HMBOX1/PATZ1 and their downstream targets, including secreted factors, contributes to the MASLD-resistant phenotype of Göttingen minipigs and may provide promising targets for the prevention and treatment of fatty liver disease. - Source: PubMed
Publication date: 2026/06/25
Gottmann PascalJonas WenkeRenner SimonePhilippou-Massier JuliaHommel TheresaDahlhoff MaikZeigerer AnjaWolf EckhardVogel HeikeSchürmann Annette - Type 1 diabetes (T1DM) is a T cell-mediated autoimmune disease. The sphingosine-1-phosphate (S1P) signaling pathway regulates lymphocyte trafficking, but its status in T1DM remains poorly characterized. This study investigated S1P and sphingosine-1-phosphate receptor 1(S1PR1) alterations in T1DM through integrated single-cell transcriptomic and clinical analysis. - Source: PubMed
Publication date: 2026/06/08
Chen DongyanZhang FuhuaRen TianChi HaiyanShen MengyangKang ShiyuLi XunLin Peng